December 12, 2019 09:18 AM ESTUpdated 09:47 AM

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line

John Carroll

Editor & Founder

Three days after Gilead’s Kite subsidiary showed off stellar data on their number 2 CAR-T KTE-X19 at ASH, the executive team has pivoted straight to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Breaking down silos with a new quantitative approach to drug development

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line